MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
24.86
-0.06
-0.24%
Pre Market: 24.08 -0.78 -3.14% 05:40 02/09 EST
OPEN
25.41
PREV CLOSE
24.92
HIGH
26.29
LOW
24.77
VOLUME
18
TURNOVER
0
52 WEEK HIGH
39.92
52 WEEK LOW
18.35
MARKET CAP
307.84M
P/E (TTM)
33.32
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XOMA last week (0202-0206)?
Weekly Report · 2h ago
XOMA Royalty Corporation veröffentlicht ergänzten Bericht zu LAVA-Legacy-Assets
Reuters · 6d ago
XOMA Royalty Corporation Issues Amendment to Report on LAVA Legacy Assets
Reuters · 6d ago
Weekly Report: what happened at XOMA last week (0126-0130)?
Weekly Report · 02/02 09:40
Weekly Report: what happened at XOMA last week (0119-0123)?
Weekly Report · 01/26 09:41
Weekly Report: what happened at XOMA last week (0112-0116)?
Weekly Report · 01/19 09:44
XOMA Royalty Appoints New Chief Financial Officer
TipRanks · 01/15 21:48
XOMA Royalty Appoints Jeffrey Trigilio CFO, Effective Jan. 12, Succeeding Thomas Burns
Benzinga · 01/15 21:28
More
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.